Skip to content

Multicenter, Randomized Controlled Clinical Study on Fangbai Granule in Preventing Recurrence of Vitiligo

Multicenter, Randomized Controlled Clinical Study on Fangbai Granule in Preventing Recurrence of Vitiligo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001730
Enrollment
Unknown
Registered
2026-07-13
Start date
2026-07-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo

Interventions

Intervention group:Fangbai Granule
Control group:Placebo of Fangbai Granules

Sponsors

Chongqing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Meeting the diagnostic criteria for stable non-segmental vitiligo; 2.Conforming to the syndrome differentiation criteria for liver-kidney deficiency pattern in traditional Chinese medicine (TCM); 3.The white macules achieving over 80% repigmentation as assessed by investigators, with an interval of no more than 6 months from the attainment of 80% repigmentation to study enrollment (for acral and hairy lesions, only stability is required, and repigmentation is not included in the evaluation); 4.Aged 18 to 65 years; 5.Voluntarily participating in the trial and signing the informed consent form (ICF).

Exclusion criteria

Exclusion criteria: Patients complicated with other skin disorders that may interfere with efficacy evaluation of the target disease; Pregnant or lactating females, as well as those planning to conceive within one year; Patients receiving oral glucocorticoids or immunosuppressants within the preceding 1 month, or topical preparations of such medications within the preceding 2 weeks; Subjects complicated with severe infection, malignant neoplasm, other autoimmune diseases, severe cardiovascular, hepatic or renal disorders and other critical systemic illnesses; Patients with known hypersensitivity to any study medication; Individuals requiring prolonged regular sun exposure; Patients deemed ineligible for enrollment upon investigator's clinical assessment; Subjects who decline to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
recurrence rate;

Secondary

MeasureTime frame
12-month recurrence rate;Cell surface markers (CD3, CD4, CD8, CD45RO, CD62L, CD197, CD25, CD127);Cytokines (HMGN1, HMGN5, IL-15, CXCL9, CXCL10);VitiQol;

Countries

China

Contacts

Public ContactLiu Yi

Chongqing hospital of traditional Chinese medicine

liuyifuzi@126.com18102383318

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026